Lynparza, Keytruda Supplemental Indications Face US FDA Panel Review

 
• By Sue Sutter
  
PS1912_Cancer-treatment_296307902_1200.jpg
US FDA's ODAC will review four cancer drugs in two days. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers